Supernus Pharmaceuticals Inc (SUPN)
Drugs • Health Care
August 03, 2026 Supernus Pharmaceuticals Faces Scrutiny Over Proposed Sale to Indivior Halper Sadeh LLC is investigating the proposed sale of Supernus Pharmaceuticals to Indivior to ensure shareholders receive fair value and full disclosure. The inquiry may lead to negotiations for a higher price and increased transparency regarding the acquisition.
August 03, 2026 Supernus Pharmaceuticals Reports Robust Q2 2026 Results Amid Strategic Merger Announcement Supernus Pharmaceuticals reported a robust 32% revenue growth in Q2 2026, driven by successful product launches and collaborations. The company announced a strategic merger with Indivior to enhance its market presence and operational efficiency. Future growth is anticipated as Supernus focuses on expanding its product portfolio for CNS disorders.
August 03, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals Announce Strategic Merger Supernus Pharmaceuticals and Indivior Pharmaceuticals have announced a strategic merger aimed at creating a leading CNS biopharmaceutical company. The deal is projected to yield $125 million in annual cost synergies and a combined revenue of $2.2 billion, enhancing innovation in CNS treatments.
August 03, 2026 Supernus Pharmaceuticals Inc. Reports Q2 2026 Financial Results Amid Strategic Merger Supernus Pharmaceuticals reported a Q2 2026 net product sales increase to $165.7 million, despite a net loss of $58.37 million. The company announced a significant merger with Indivior Pharmaceuticals aimed at strengthening its market position amidst operational challenges.
July 14, 2026 Supernus Pharmaceuticals Celebrates Milestone in ADHD Treatment with Qelbree's Five-Year Anniversary Supernus Pharmaceuticals marks the five-year anniversary of Qelbree's FDA approval, highlighting its significance as the first non-stimulant ADHD treatment for adults in two decades. With over 3 million prescriptions filled, Qelbree continues to provide innovative treatment options, reflecting the company's commitment to the ADHD community.
May 27, 2026 Supernus Pharmaceuticals Set to Showcase Growth at Upcoming Investor Conferences Supernus Pharmaceuticals is preparing to showcase its growth and innovations at the Jefferies and Goldman Sachs healthcare conferences in June 2026. The company aims to engage investors by highlighting its robust portfolio and future developments in CNS disorders.
May 06, 2026 Supernus Pharmaceuticals to Showcase Innovations at Bank of America Health Care Conference Supernus Pharmaceuticals will participate in the Bank of America Health Care Conference on May 12, 2026, featuring a fireside chat with CEO Jack A. Khattar. The event aims to highlight the company’s advancements in CNS disease treatments and engage with investors about future strategies.
May 05, 2026 Supernus Pharmaceuticals Inc. Reports Strong Growth in Q1 2026 Supernus Pharmaceuticals, Inc. announced a significant revenue increase in Q1 2026, driven by strong sales of key CNS products. Despite a net loss improvement and rising expenses, the company is poised for future growth amid operational challenges.
May 05, 2026 Supernus Pharmaceuticals Reports Strong Q1 2026 Financial Results Supernus Pharmaceuticals achieved a remarkable 56% increase in revenue for Q1 2026, driven by strong sales of products like ONAPGO and ZURZUVAE. The company highlights a positive outlook with a solid cash position and a promising pipeline of new treatments. Investors are optimistic about the company's growth potential in the CNS market.
April 22, 2026 Supernus Pharmaceuticals Prepares for Q1 2026 Financial Results Announcement Supernus Pharmaceuticals is set to announce its financial results for Q1 2026 on May 5, followed by a conference call with key executives. The company continues to focus on CNS disease treatments and will address future challenges and opportunities during the call.
March 02, 2026 Supernus Pharmaceuticals Inc. Reports 2025 Annual Results: Navigating Change Amidst Challenges In its 2025 annual report, Supernus Pharmaceuticals highlights the acquisition of Sage Therapeutics and a notable net loss of $38.6 million. Despite challenges, the company remains focused on expanding its CNS treatment portfolio, with several promising product candidates in development.
February 24, 2026 Supernus Pharmaceuticals Reports Record Financial Results for Q4 and Full Year 2025 Supernus Pharmaceuticals achieved record financial results for Q4 and full year 2025, with a 21% revenue increase in Q4. The company highlights strong product sales and strategic acquisitions, positioning itself for continued growth in 2026.
February 23, 2026 Supernus Pharmaceuticals to Showcase Innovations at March Investor Conferences Supernus Pharmaceuticals will showcase its innovations in CNS treatments at three major investor conferences in March 2026. The company aims to engage with investors through presentations and webcasts, highlighting its commitment to advancing therapies for various CNS conditions.
February 12, 2026 Supernus Pharmaceuticals Set to Announce Fourth Quarter and Full Year 2025 Financial Results Supernus Pharmaceuticals is set to announce its Q4 and full year 2025 financial results on February 24, 2026. The company, known for its CNS disorder treatments, will discuss key performance metrics and strategic directions in a conference call following the announcement.
December 03, 2025 Supernus Pharmaceuticals Set to Present at Bank of America Securities 2025 CNS Therapeutics Virtual Conference Supernus Pharmaceuticals will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025. CEO Jack A. Khattar will discuss the company's strategic initiatives and innovations in CNS disease treatments. Stakeholders can access a live webcast and archived replay for updates.
November 21, 2025 Supernus Pharmaceuticals Set to Showcase at Piper Sandler Annual Healthcare Conference Supernus Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. CEO Jack Khattar will share insights on the company's advancements in CNS treatments and future strategies, fostering engagement with investors and stakeholders.
November 12, 2025 Supernus Pharmaceuticals to Showcase Leadership at Jefferies Global Healthcare Conference Supernus Pharmaceuticals will present at the 2025 Jefferies Global Healthcare Conference, highlighting its commitment to CNS disease treatments and innovations. CEO Jack A. Khattar will lead discussions on strategic growth and future opportunities in the biopharmaceutical sector.
November 06, 2025 Supernus Pharmaceuticals Inc. Reports Q3 2025 Financial Performance Amidst Strategic Acquisition Supernus Pharmaceuticals Inc. reported its Q3 2025 financials, revealing a slight decline in sales but significant growth in CNS product sales. The strategic acquisition of Sage Therapeutics aims to enhance their portfolio and expand market reach.
November 04, 2025 Supernus Pharmaceuticals Reports Strong Third Quarter 2025 Results Supernus Pharmaceuticals reported impressive financial results for Q3 2025, driven by strong sales from products like ONAPGO and Qelbree. The company faces operational challenges, including supplier constraints, but remains optimistic about future growth and product pipeline developments.
October 21, 2025 Supernus Pharmaceuticals Set to Announce Q3 2025 Financial Results Supernus Pharmaceuticals will announce its Q3 2025 financial results on November 4, led by CEO Jack Khattar. The call will include a Q&A session and insights into the company’s CNS treatment pipeline and strategies.
August 05, 2025 Supernus Pharmaceuticals Inc. Reports Q2 2025 Financial Results: Strategic Acquisitions and Market Adaptations Supernus Pharmaceuticals reported Q2 2025 net product sales of $158 million, facing challenges from competition but showing growth in key products. The strategic acquisition of Sage Therapeutics aims to enhance its CNS offerings despite integration hurdles. With a solid cash position, Supernus is poised for future growth.
May 06, 2025 Supernus Pharmaceuticals Inc. Reports Strong Q1 2025 Results Amidst New Product Launches Supernus Pharmaceuticals reported $142 million in net product sales for Q1 2025, aided by the launch of ONAPGO™ for Parkinson’s Disease. Despite a net income loss of $11.8 million, the company is optimistic about future growth due to robust R&D investments and a strong financial position.
March 04, 2025 Supernus Pharmaceuticals Inc. Announces Participation in Key Investor Conferences Supernus Pharmaceuticals, Inc. will have its CEO Jack Khattar speak at two significant investor conferences in March 2025, focusing on biopharmaceutical advancements. The company emphasizes investor relations and will provide a live webcast of the event, showcasing its innovative CNS treatments.
February 27, 2025 Supernus Pharmaceuticals Set to Showcase Innovations at TD Cowen Health Care Conference Supernus Pharmaceuticals will present at the TD Cowen Health Care Conference on March 3, 2025, led by CEO Jack A. Khattar. The company focuses on advancing treatments for CNS disorders and will discuss its strategic direction and innovations during the event.
February 25, 2025 Supernus Pharmaceuticals Inc. Reports Strong Growth in 2024 Annual Financial Results Supernus Pharmaceuticals Inc. has reported strong growth in its 2024 annual financial results, with a remarkable increase in net product sales and net income. Despite facing challenges with certain products, the company’s effective cost management and promising pipeline projects position it well for future growth.
February 20, 2025 SWOT Analysis of Supernus Pharmaceuticals Inc. in 2025 This SWOT analysis of Supernus Pharmaceuticals Inc. in 2025 highlights the company’s strong market position in CNS therapeutics, alongside vulnerabilities and emerging opportunities. It underscores the need for strategic management to navigate a competitive landscape marked by regulatory challenges and market dynamics.
February 18, 2025 Supernus Pharmaceuticals Faces Setback in Phase 2b Study for Treatment-Resistant Depression Supernus Pharmaceuticals reported disappointing results from its Phase 2b study of SPN-820 for treatment-resistant depression, showing no significant improvement over placebo. The company's CEO expressed disappointment while indicating future analyses and discussions with their development partner, Navitor Pharmaceuticals.
February 11, 2025 Supernus Pharmaceuticals Inc. to Discuss 2024 Financial Results in Upcoming Conference Call Supernus Pharmaceuticals will host a conference call on February 25, 2025, to discuss its financial results for Q4 and the full year of 2024. CEO Jack Khattar and CFO Tim Dec will provide insights into the company's performance, with a Q&A session to follow. A live webcast and a replay will be available for those who cannot attend.
November 04, 2024 Supernus Pharmaceuticals Reports Strong Q3 2024 Financial Results Supernus Pharmaceuticals has reported a notable 14.1% increase in revenue for Q3 2024, driven by rising product sales and enhanced operational efficiency. The company's commitment to innovation in CNS treatments is reflected in its impressive financial turnaround and positive cash flow positions.
August 06, 2024 Supernus Pharmaceuticals Inc. Reports Strong Q2 2024 Results, Highlighting Growth and Strategic Pipeline Developments Supernus Pharmaceuticals Inc. reported impressive Q2 2024 results, with revenues of $162.5 million and a net income recovery to $19.91 million. The company is advancing its product pipeline, particularly for ADHD and Parkinson's disease, positioning itself for future growth.
May 08, 2024 Supernus Pharmaceuticals Inc. Reports Q1 2024 Financial Results Supernus Pharmaceuticals Inc. released its Q1 2024 financial results, showing a revenue decline of 2% to $2.1 million and a significant drop in net income. Despite challenges, the company maintains a solid cash position and continues investing in its CNS product pipeline, indicating potential for future growth.